RA is known to be associated with an increased risk of serious infection. Even more than 50
years ago, observational studies showed a greater than 2-fold increased risk of serious …

There is convincing evidence for the known and unambiguously accepted beneficial effects
of glucocorticoids at low dosages. However, the implementation of existing …

Objectives This meta-analysis investigates the efficacy of tumour necrosis factor α (TNFα)
blockers versus placebo for the treatment of ankylosing spondylitis (AS) and non-radiographic …

Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there
is no widely used definition of remission that is stringent but achievable and could be …

Objective Ankylosing spondylitis (AS) is diagnosed late, because radiographs of the sacroiliac
joints often do not show definite sacroiliitis at the time of disease onset. The aim of this …

… a duration of back pain of >3 months, and this parameter was therefore not listed separately.
… a duration of back pain of >3 months, and this parameter was therefore not listed separately. …

Objective To estimate the incidence rates of serious and nonserious infections in patients
with rheumatoid arthritis (RA) who start treatment with a biologic agent, and to compare these …

Objectives: To evaluate various validity aspects of four disease activity scores (ASDAS) for
ankylosing spondylitis (AS) in comparison with the Bath Ankylosing Spondylitis Disease …

Background: TNFα blockers have been shown to be highly efficacious in patients with active
ankylosing spondylitis (AS). Objective: To identify parameters predicting the clinical …

Objective To assess prospectively the rates and to explore predictors of spinal radiographic
progression over 2 years in a cohort of patients with early axial spondylarthritis (SpA). …